236 related articles for article (PubMed ID: 8807890)
1. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Mello JA; Acharya S; Fishel R; Essigmann JM
Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890
[TBL] [Abstract][Full Text] [Related]
2. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
3. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
4. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
[TBL] [Abstract][Full Text] [Related]
5. Recognition and repair of DNA-cisplatin adducts.
Woźniak K; Błasiak J
Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
Zhai X; Beckmann H; Jantzen HM; Essigmann JM
Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
[TBL] [Abstract][Full Text] [Related]
7. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin.
Trimmer EE; Essigmann JM
Essays Biochem; 1999; 34():191-211. PubMed ID: 10730196
[TBL] [Abstract][Full Text] [Related]
9. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
Zhu G; Myint M; Ang WH; Song L; Lippard SJ
Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
[TBL] [Abstract][Full Text] [Related]
10. Binding of the Escherichia coli UvrAB proteins to the DNA mono- and diadducts of cis-[N-2-amino-N-2-methylamino-2,2,1-bicycloheptane]dichloroplatinum(II ) and cisplatin. Analysis of the factors controlling recognition and proof of monoadduct-mediated UvrB-DNA cross-linking.
Lambert B; Jestin JL; Bréhin P; Oleykowski C; Yeung AT; Mailliet P; Prétot C; Le Pecq JB; Jacquemin-Sablon A; Chottard JC
J Biol Chem; 1995 Sep; 270(36):21251-7. PubMed ID: 7673159
[TBL] [Abstract][Full Text] [Related]
11. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
[TBL] [Abstract][Full Text] [Related]
12. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
13. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
14. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
Zdraveski ZZ; Mello JA; Farinelli CK; Essigmann JM; Marinus MG
J Biol Chem; 2002 Jan; 277(2):1255-60. PubMed ID: 11705991
[TBL] [Abstract][Full Text] [Related]
15. Human MutSalpha specifically binds to DNA containing aminofluorene and acetylaminofluorene adducts.
Li GM; Wang H; Romano LJ
J Biol Chem; 1996 Sep; 271(39):24084-8. PubMed ID: 8798646
[TBL] [Abstract][Full Text] [Related]
16. MutS inhibits RecA-mediated strand exchange with platinated DNA substrates.
Calmann MA; Marinus MG
Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14174-9. PubMed ID: 15375217
[TBL] [Abstract][Full Text] [Related]
17. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins.
Kaspárková J; Brabec V
Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
19. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.
Novakova O; Kasparkova J; Malina J; Natile G; Brabec V
Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903
[TBL] [Abstract][Full Text] [Related]
20. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA.
Yaneva J; Leuba SH; van Holde K; Zlatanova J
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13448-51. PubMed ID: 9391045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
